Detalhe da pesquisa
1.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
2.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med
; 387(24): 2232-2244, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507686
3.
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Br J Haematol
; 203(5): 736-746, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287117
4.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica
; 108(8): 2192-2204, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546453
5.
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(18): 1235-1247, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37403937
6.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
7.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288
8.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966625
9.
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 96(2): 226-233, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125764
10.
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Am J Hematol
; 96(4): 428-435, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33421178
11.
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Future Oncol
; 17(19): 2499-2512, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769076
12.
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Br J Haematol
; 188(3): 404-412, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31468521
13.
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Blood
; 131(8): 855-863, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29203585
14.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Blood
; 131(13): 1415-1424, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29348128
15.
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Blood
; 131(24): 2661-2669, 2018 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29724899
16.
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Invest New Drugs
; 38(5): 1448-1453, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32125598
17.
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
Lancet Oncol
; 20(6): e302-e312, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31162104
18.
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.
Oncologist
; 24(8): 1035-e623, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31073022
19.
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Am J Hematol
; 94(12): 1325-1334, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31490009
20.
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
Am J Hematol
; 94(7): 794-802, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31021005